Why the study?
Does ambrisentan improve exercise pulmonary vascular resistance in patients with systemic sclerosis spectrum-associated exercise-induced pulmonary hypertension?
Population
12 patients with systemic sclerosis spectrum-associated exercise-induced pulmonary hypertension defined as…
Design
Cohort, open-label
Follow-up
24 weeks
Authors
Loading...
Ambrisentan may benefit SSc-associated exercise PH; hypothesis-generating and leaves open need for RCTs before practice change.
Does ambrisentan improve exercise pulmonary vascular resistance in patients with systemic sclerosis spectrum-associated exercise-induced pulmonary hypertension?
In a small pilot study, ambrisentan improved exercise hemodynamics and exercise capacity over 24 weeks in patients with systemic sclerosis-associated exercise-induced pulmonary hypertension.
Saggar et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: